No Data
No Data
Nurix Therapeutics Presents Data at AACR 2025 Highlighting Transformative Potential of Proprietary DEL-AI Platform Leveraging Machine Learning To Speed Discovery Of Novel Drugs
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting From Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
Cathie Wood Buys More NVIDIA And AMD Stock As Chinese Tech Giants Stockpile Chips Amid Looming US Export Curbs
Analysts' Revenue Estimates For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher
Nurix Therapeutics Says FDA Clears IND for IRAK4 Degrader GS-6791/NX-0479, Enabling Initiation Of Phase 1 Trial, Which Is Expected To Begin in Q2 2025
Express News | Nurix Therapeutics Inc - to Receive $5 Million Milestone Payment From Gilead